Head of Pharmacology

Xiaohe Shi, PhD. has a B.S. in Pharmacology from Peking University, a PhD in Biology from the Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and a Senior Research Fellow at the Bioimaging Consortium/IMCB in Singapore. Xiaohe Shi, PhD was the senior director of in vivo oncology, immunology and pharmacology research at one of the world's most prestigious CROs in China, where he built and led a team of over 70 researchers to provide cancer pharmacology testing services to over 50 overseas companies (including most of the world's top 20 pharmaceutical and biotech companies) and several biotech companies in China.

Dr. Shi has more than 15 years of extensive research experience in cancer and immunology, working on the groundbreaking ADC drug approved by FDA as an orphan cancer drug in 2019, as well as preparing preclinical data for seven drugs prior to IND submission in the US and China. Dr. Shi has published 28 SCI papers with more than 2000 citations.